ClinicalTrials.Veeva

Menu

Study on Allopregnanolone and Depression in Women Across the Menopause Transition (SADIE-P)

Mass General Brigham logo

Mass General Brigham

Status

Enrolling

Conditions

Depression

Treatments

Other: placebo
Dietary Supplement: pregnenolone

Study type

Interventional

Funder types

Other

Identifiers

NCT06238700
2024P000113

Details and patient eligibility

About

This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.

Full description

Midlife women are burdened with depression risk that is at least partly attributed to changing reproductive steroid dynamics across a prolonged reproductive transition. We hypothesize that declining endogenous allopregnanolone (ALLO) levels across the menopause transition underlies perimenopausal depression. This mechanistic trial aims to amplify the contrast between lower endogenous ALLO levels in perimenopausal women and higher levels induced by pregnenolone. This will be achieved by using the over-the-counter dietary supplement, pregnenolone, in a randomized, double-blind, parallel-arm, placebo-controlled trial. By manipulating ALLO levels together with key measurement of depression domains, this study harnesses the endocrine biology of perimenopause to explicate behavioral and neurobiological mechanisms underlying depression in women across the menopause transition.

Enrollment

80 estimated patients

Sex

Female

Ages

40 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Healthy women ages 40 to 60 years in the menopause transition
  • Depressive symptoms
  • Psychotropic medications are allowed if the dose is stable prior to screening and throughout the study
  • Able to read Arabic numerals and perform simple arithmetic
  • Able to provide written informed consent

Exclusion criteria

  • Systemic hormone therapy
  • Contraindicated medications with pregnenolone
  • Systemic corticosteroid
  • Other psychiatric illnesses that are considered to be primary
  • Current suicidal ideation
  • Active substance use disorders
  • Unstable medical conditions
  • Obstructive sleep apnea or other primary sleep disorders
  • Abnormal hepatic and renal function
  • Known allergy to progesterone, exogenous allopregnanolone, or pregnenolone
  • History of head injury resulting in loss of consciousness > 20 min
  • Inability to comply with barrier contraceptive methods
  • Known intellectual disability
  • Investigator judgement that study participation constitutes substantial risk given medical or psychiatric condition
  • Current or recent participation in clinical trial expected to interfere with risk of or interpretation of study data
  • Inability to comply with study procedures

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

80 participants in 2 patient groups, including a placebo group

pregnenolone
Experimental group
Description:
Participants will take 250mg of pregnenolone twice per day (daily total=500mg) for four weeks
Treatment:
Dietary Supplement: pregnenolone
placebo
Placebo Comparator group
Description:
Participants will take placebo twice per day for four weeks
Treatment:
Other: placebo

Trial contacts and locations

1

Loading...

Central trial contact

Aleta Wiley, MPH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems